Thought Leader, New Marketplace

Aaron S. Kesselheim, MD, JD, MPH

Associate Professor of Medicine
Harvard Medical School


Aaron Kesselheim, MD, JD, MPH, is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research center that focuses on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, and has been asked to serve on select advisory committees for the FDA and National Academies of Science, Engineering, and Medicine. Aaron also serves as a Visiting Associate Professor of Law at Yale Law School, where he teaches a yearly course on Food and Drug Administration Law, and as a faculty member at the Harvard Medical School Center for Bioethics. He is the author of over 250 articles in the peer-reviewed medical and health policy literature and serves as Editor-in-Chief of the Journal of Law, Medicine, and Ethics.

U.S. and Canadian Prices of Some Generic Drugs with U.S. Prices That Recently Increased by 1000% or More

New Marketplace

The Price of Crossing the Border for Medications

The health and safety risks faced by the many Americans who cannot afford medications necessitate consideration of alternative strategies to provide less expensive medications.

Value-Based Drug Pricing Is Not a Fair Fight Panel Clip Still

New Marketplace

Drug Pricing Is Not a Fair Fight

A payer describes the barriers in moving toward value-based drug pricing.

New Marketplace

Can Transparency Legislation Help Control Medication Costs?

Spending on prescription drugs has shot up. Ten states are debating transparency laws to require pharmaceutical companies to disclose research and development costs. Here’s why that effort is unlikely to work.

Insights Council

Have a voice. Join other health care leaders effecting change, shaping tomorrow.

Apply Now